Dermatology Immune Response Scientist 
XTalks
JUNE 10, 2024
Related: Sotyktu (deucravacitinib) Gets FDA Approval for Moderate-to-Severe Plaque Psoriasis Sotyktu’s effectiveness stems from its selective inhibition of tyrosine kinase 2 (TYK2), a key enzyme involved in the pathogenesis of many immune-mediated inflammatory diseases. More About Psoriasis About 7.55
Olympian Clinical Research
NOVEMBER 16, 2022
According to the American Academy of Dermatology , scientists believe that when a hair follicle becomes clogged with keratin, bacteria breed within it. HS is believed to develop due to an immune response that generates too much inflammation. Possible Causes of Hidradenitis Suppurativa.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 9, 2021
Deucravacitinib (pronounced doo-krav-a-sih-ti-nib) is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action and is the first and only selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Deucravacitinib is not approved for use in any country.
The Pharma Data
JUNE 19, 2022
Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. They conducted their first experiment with cultured mouse melanoma cells.
The Pharma Data
AUGUST 11, 2020
Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Immune-Mediated Skin and Dermatologic Adverse Reactions. About Opdivo.
The Pharma Data
AUGUST 11, 2020
Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Immune-Mediated Skin and Dermatologic Adverse Reactions. About Opdivo.
Expert insights. Personalized for you.
52 
Let's personalize your content